Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

Core Insights - Alpha Teknova, Inc. has partnered with Pluristyx, Inc. to exclusively distribute the PluriFreeze™ cryopreservation system, enhancing the development of cell therapies [1][2] - The PluriFreeze system is designed to streamline the commercialization of allogeneic cell therapies, featuring a synthetic and animal-origin-free formulation [2][3] Company Overview - Teknova specializes in producing critical reagents for the life sciences sector, focusing on novel therapies, vaccines, and molecular diagnostics since 1996 [5] - Pluristyx is a biotechnology company that provides a range of products and services for cell and gene therapy development, including induced Pluripotent Stem Cells (iPSCs) [6] Product Details - The PluriFreeze system includes PluriFreeze Base, a cellular wash that mimics intracellular space, and PluriFreeze PF10, a low viscosity freezing medium with 10% DMSO [2][3] - Research-grade pricing for PluriFreeze Base starts at $240 per 100 mL, while PluriFreeze PF10 starts at $260 per 100 mL [3] Collaboration Benefits - The collaboration allows for better control and optimization of biopreservation conditions, facilitating the scaling of cell therapy development [3] - Customers can access both RUO and GMP-grade versions of the PluriFreeze products, with options for custom formulations [3]